Pharmaceutical Technology lists ten of the most popular tweets on oncology in February 2020, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked by GlobalData’s Influencer Platform, which is based on a scientific process that works on pre-defined parameters. Influencers are selected after a deep analysis of the influencer’s relevance, network strength, engagement, and leading discussions on new and emerging trends.
Top tweets on oncology in February 2020
1. Eric Topol’s tweet on the promises and challenges of genome editing
Eric Topol, founder and director of the Scripps Research Translational Institute, shared an article on the therapeutic opportunities and challenges of genome editing. The article further noted the use of CRISPR (clustered regularly interspaced short palindromic repeats) oncology technology for treatment in humans. Genome editing can be applied to several diseases such as Duchenne muscular dystrophy and sickle disease anaemia. It is being tested for further therapeutic applications.
The #CRISPR human genome editing review I've been waiting for, from/by Jennifer @doudna_lab @nature https://t.co/AlzDPqg9yT pic.twitter.com/rxXkf89Gfz
— Eric Topol (@EricTopol) February 12, 2020
Username: Eric Topol
Twitter handle: @EricTopol
2. Atul Gawande’s tweet on the lapses in oncology medical care for sick inmates
Atul Gawande, founder and chairman of Ariadne Labs, shared an article on how Alabama sheriffs are releasing sick or injured jail inmates to evade medical bills. The article further noted that these inmates were rearrested when they recovered, and that many have died due to substandard treatment being given to sick oncology inmates.
The article gives an account of many inmates being released due to medical emergencies under the ‘medical bond’ clause, which the sheriffs were following in local jails across the country.
Ironically, in prison they will be forced to cover the chemotherapy costs for the young woman. In some places, inmates are being released just to avoid paying their medical bills—and then rearrested when they have recovered. https://t.co/BHHa4fCORb
— Atul Gawande (@Atul_Gawande) February 2, 2020
Username: Atul Gawande
Twitter handle: @Atul_Gawande
3. Jennifer Gunter’s oncology tweet on Reiki being ineffective
Jennifer Gunter, an obstetrician-gynaecologist, tweeted on Reiki trials being ineffective in improving outcomes. The influencer stated that people did better with chemotherapy when they had companionship.
I love that Reiki trial because the nurse doing math calculations had the same effect as the Reiki practioner. Both were more effective that having no attendant. Conclusion: people do better with chemo when they have companionship.
— Jennifer Gunter (@DrJenGunter) February 4, 2020
Username: Jennifer Gunter
Twitter handle: @DrJenGunter
4. Liz O’Riordan’s tweet on a photographic exhibition plan to help breast cancer patients cope better
Liz O’Riordan, a consultant breast cancer surgeon, shared an article on how photography can be used to help patients relate with breast cancer. The influencer noted that her own photographs after having undergone a mastectomy seemed empowering and therapeutic.
The article further noted that the influencer is looking to create a photographic exhibition along with photographer Alex Kilbeeto, to shed light on the emotions of breast cancer survivors.
The power of art to heal…
Read how I'm using photography to help patients with breast cancer explore how they relate to their illness with @AlexKilbee https://t.co/zANrHmvqqs
— Liz O'Riordan 💋🦔🇪🇺 (@Liz_ORiordan) February 23, 2020
Username: Liz O’Riordan
Twitter handle: @Liz_ORiordan
5. Anirban Maitra’s tweet on increased intratumoural heterogeneity in small-cell lung cancer
Anirban Maitra, the scientific director of the Ahmed Center for Pancreatic Cancer Research, shared an article on the increased occurrence of tumours following the beginning of therapy resistance in situations such as small-cell lung cancer (SCLC). The article further noted that clinical efforts should be focused on rational combination therapies to counter the occurrence of ITH and other resistance mechanisms.
Single-cell analyses reveal increased intratumoral heterogeneity (ITH) after the onset of therapy resistance in small-cell #lungcancer
From Lauren Byers @CancerMedMDA & numeorus @MDAndersonNews colleagues in @NatureCancer https://t.co/IZhEmBwE4G
— Anirban Maitra (@Aiims1742) February 17, 2020
Username: Anirban Maitra
Twitter handle: @Aiims1742
6. FabriceAndre’s tweet on chemotherapy and pembrolizumab for high-risk, early-stage breast cancer
FabriceAndre, an oncologist at Gustave Roussy, shared an article on a study to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy and pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC). The study confirmed manageable toxicity and promising antitumor activity.
Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: 60% pathological complete response, high TILs and/or PDL1 = higher pCR. by P Schmid, @LoiSher and coll https://t.co/93DZz0LwoI
— FabriceAndre (@FAndreMD) February 15, 2020
Twitter handle: @FAndreMD
7. G Garcia-Manero’s tweet on blood advances
G Garcia-Manero, a Leukaemia physician and professor of medicine, shared an article on the analysis of the impact of p53 mutation in Myelodysplastic syndromes (MDS). The study evaluated the type, number, and patterns of TP53 mutations in response outcomes and development of MDS.
Our latest paper out in Blood Advances: analysis of impact of p53 mutation in MDS. Congratulations to Dr Montalban-Bravo for this efforthttps://t.co/748jODsRSC
— G Garcia-Manero (@garciamanero) February 7, 2020
Username: G Garcia-Manero
Twitter handle: @garciamanero
8. David Gandara’s tweet on the first potential treatment for non-small cell lung cancer
David Gandara, a medical oncologist and clinical-translational researcher in lung cancer, shared an article on the FDA’s acceptance and priority review of capmatinib (INC280) for treating patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer (NSCLC).
Capmatinib (INC280) is an investigational, oral, and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009.
New therapy may be coming for MET Ex14-mutated NSCLC. Another reason to do broad genomic testing up front. If you don’t look you will not find! MET inhibitor capmatinib (INC280), ORR of 68% in METex14 mutated advanced NSCLC, granted priority FDA review https://t.co/7AtWLZH1gr
— David Gandara (@drgandara) February 11, 2020
Username: David Gandara
Twitter handle: @drgandara
9. Julie Gralow’s oncology tweet on how to manage male breast cancer
Julie Gralow, the director of breast medical oncology at Seattle Cancer Care Alliance, shared an article on ways to manage male breast cancer. The guideline developed recommendations based on formal consensus and review. It stated that most of the approaches were similar to that for women. Drug administration, annual mammograms, genetic counselling, and germline genetic testing were some of the listed approaches.
New @asco guideline on management of male breast cancer. https://t.co/z2pQzXStyb
— Julie Gralow (@jrgralow) February 24, 2020
Username: Julie Gralow
Twitter handle: @jrgralow
10. Vincent Rajkumar’s tweet on the utility of serum free light chain ratio in response assessment in myeloma
Vincent Rajkumar, a professor of medicine at the Mayo Clinic, shared an article on the utility of serum free light chain (FLC) ratio in response definition in patients with multiple myeloma. The study suggested that the sFLC ratio should be interpreted with caution, especially in the setting of complete response.
Utility of serum free light chain (FLC) ratio in response assessment in myeloma @BloodAdvances @BloodJournal @ASH_hematology @MayoMyeloma @MayoClinic @mtmdphd @MyelomaTeacher @NorthTxMSG https://t.co/ENpzlscPBP
— Vincent Rajkumar (@VincentRK) February 15, 2020
Username: Vincent Rajkumar
Twitter handle: @VincentRK